Research ExplorerPublicationsPharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 P...

Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis

Standard

Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis. / Lingscheid, Tilman; Kinzig, Martina; Krüger, Anne; Müller, Nils; Bölke, Georg; Tober-Lau, Pinkus; Münn, Friederike; Kriedemann, Helene; Witzenrath, Martin; Sander, Leif E; Sörgel, Fritz; Kurth, Florian.

In: ANTIMICROB AGENTS CH, Vol. 66, No. 11, e0122922, 15.11.2022.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lingscheid, T, Kinzig, M, Krüger, A, Müller, N, Bölke, G, Tober-Lau, P, Münn, F, Kriedemann, H, Witzenrath, M, Sander, LE, Sörgel, F & Kurth, F 2022, 'Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis', ANTIMICROB AGENTS CH, vol. 66, no. 11, e0122922. https://doi.org/10.1128/aac.01229-22

APA

Lingscheid, T., Kinzig, M., Krüger, A., Müller, N., Bölke, G., Tober-Lau, P., Münn, F., Kriedemann, H., Witzenrath, M., Sander, L. E., Sörgel, F., & Kurth, F. (2022). Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis. ANTIMICROB AGENTS CH, 66(11), [e0122922]. https://doi.org/10.1128/aac.01229-22

Vancouver

Lingscheid T, Kinzig M, Krüger A, Müller N, Bölke G, Tober-Lau P et al. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis. ANTIMICROB AGENTS CH. 2022 Nov 15;66(11). e0122922. https://doi.org/10.1128/aac.01229-22

Bibtex

@article{636b85a86f2c47548e7beb91426c76f0,
title = "Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis",
abstract = "Nirmatrelvir/ritonavir is an effective antiviral therapy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Use is not recommended in patients with end-stage renal disease (ESDR) due to a lack of data. We investigated the pharmacokinetics of nirmatrelvir/ritonavir (150 mg/100 mg twice a day) in four patients with ESRD undergoing hemodialysis. Nirmatrelvir peak concentrations ranged from 4,563 to 7,898 ng/mL and declined after hemodialysis. Concentrations were up to 4-fold higher but still within the range known from patients without ESRD, without accumulation of nirmatrelvir after the end of treatment.",
keywords = "Humans, Ritonavir/therapeutic use, SARS-CoV-2, Kidney Failure, Chronic/drug therapy, Renal Dialysis, Antiviral Agents/therapeutic use, COVID-19 Drug Treatment",
author = "Tilman Lingscheid and Martina Kinzig and Anne Kr{\"u}ger and Nils M{\"u}ller and Georg B{\"o}lke and Pinkus Tober-Lau and Friederike M{\"u}nn and Helene Kriedemann and Martin Witzenrath and Sander, {Leif E} and Fritz S{\"o}rgel and Florian Kurth",
year = "2022",
month = nov,
day = "15",
doi = "10.1128/aac.01229-22",
language = "English",
volume = "66",
journal = "ANTIMICROB AGENTS CH",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

RIS

TY - JOUR

T1 - Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis

AU - Lingscheid, Tilman

AU - Kinzig, Martina

AU - Krüger, Anne

AU - Müller, Nils

AU - Bölke, Georg

AU - Tober-Lau, Pinkus

AU - Münn, Friederike

AU - Kriedemann, Helene

AU - Witzenrath, Martin

AU - Sander, Leif E

AU - Sörgel, Fritz

AU - Kurth, Florian

PY - 2022/11/15

Y1 - 2022/11/15

N2 - Nirmatrelvir/ritonavir is an effective antiviral therapy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Use is not recommended in patients with end-stage renal disease (ESDR) due to a lack of data. We investigated the pharmacokinetics of nirmatrelvir/ritonavir (150 mg/100 mg twice a day) in four patients with ESRD undergoing hemodialysis. Nirmatrelvir peak concentrations ranged from 4,563 to 7,898 ng/mL and declined after hemodialysis. Concentrations were up to 4-fold higher but still within the range known from patients without ESRD, without accumulation of nirmatrelvir after the end of treatment.

AB - Nirmatrelvir/ritonavir is an effective antiviral therapy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Use is not recommended in patients with end-stage renal disease (ESDR) due to a lack of data. We investigated the pharmacokinetics of nirmatrelvir/ritonavir (150 mg/100 mg twice a day) in four patients with ESRD undergoing hemodialysis. Nirmatrelvir peak concentrations ranged from 4,563 to 7,898 ng/mL and declined after hemodialysis. Concentrations were up to 4-fold higher but still within the range known from patients without ESRD, without accumulation of nirmatrelvir after the end of treatment.

KW - Humans

KW - Ritonavir/therapeutic use

KW - SARS-CoV-2

KW - Kidney Failure, Chronic/drug therapy

KW - Renal Dialysis

KW - Antiviral Agents/therapeutic use

KW - COVID-19 Drug Treatment

U2 - 10.1128/aac.01229-22

DO - 10.1128/aac.01229-22

M3 - SCORING: Journal article

C2 - 36286542

VL - 66

JO - ANTIMICROB AGENTS CH

JF - ANTIMICROB AGENTS CH

SN - 0066-4804

IS - 11

M1 - e0122922

ER -